NEW YORK – Patients with TP53-mutated pancreatic ductal adenocarcinoma, or PDAC, may respond better to adjuvant treatment with the chemotherapy drug gemcitabine (Gemzar) than patients with TP53-wildtype tumors, according to a new study published in Clinical Cancer Research.